Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CRVS · as of Jun 8, 2026
Key Statistics
Explore Corvus Pharmaceuticals, Inc. Data
crvs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 92.3%
The CRVS analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $33.17, representing +198.29% upside from the current price of $11.12.
Competitors & Peers
crvs competitorsCRVS
ABSI
AKBA
CMPX
GOSS
KALVStock Performance
Full HistoryAbout Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-…
what is corvus pharmaceuticals, inc. · crvs stock overview · corvus pharmaceuticals, inc. company profile · who is corvus pharmaceuticals, inc. ceo · crvs NASDAQ · corvus pharmaceuticals, inc. headquarters · corvus pharmaceuticals, inc. business segments
About Stock Overview & Key Data
Corvus Pharmaceuticals, Inc. (CRVS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 23, 2016. As of the latest trading session, CRVS stock price is $11.12, with a market capitalization of $935.1M. The stock has returned +175.25% over the past 12 months and +44.42% year-to-date.
According to 13 Wall Street analysts, the consensus rating for Corvus Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $33.17. In fiscal year 2025, Corvus Pharmaceuticals, Inc. reported revenue of — and net income of -$15.3M. For detailed data — including Corvus Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Corvus Pharmaceuticals, Inc. (CRVS) stock price is $11.12. The stock is traded on NASDAQ under the ticker symbol CRVS. The 52-week range is $3.55 – $26.95.